Mitochondrial DNA Instability and ZBP1 in chemotherapy-related heart damage
Official title: Mitochondrial DNA Instability and ZBP1 Activation in Anthracycline-Induced Cardiotoxicity
Funded at Jackson Laboratory · NIH-11376647 · Data updated 2026-11-12
This grant tests how a heart-protective pathway involving ZBP1 might prevent heart damage caused by common cancer drugs like doxorubicin.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jackson Laboratory NIH-funded |
| Lab location | 1 site (Bar Harbor, United States) |
| Project start | August 5, 2020 |
| Project end | April 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $882,234 |
| NIH project number | 2R01HL148153-07 |
| Project ID | NIH-11376647 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients whose cancer treatment includes anthracyclines like doxorubicin and who may be at risk for cardiotoxicity.
✕Less likely to help
People not exposed to anthracycline therapy or without cardiac risk factors related to these drugs are less likely to benefit from this work.
What this research studies
If successful, the research will look at how certain genetic signals in heart cells respond to doxorubicin and contribute to heart damage over time. The team will study mouse models and heart cells to understand why mitochondria fail and how cell death and remodeling occur after treatment. The goal is to identify markers that flag who is at risk and to explore ideas for therapies that could keep the heart healthy during and after cancer treatment. This work focuses on mechanisms that could lead to new ways to prevent or mitigate anthracycline-induced cardiotoxicity.
Why it matters
Potential benefit: A deeper understanding of why some patients experience heart damage from cancer drugs could lead to strategies to prevent it and improve survivorship.
How similar studies have gone: Previous findings show that ZBP1 influences mitochondrial decline and heart function in this context, suggesting potential for translational impact.
Where this research is happening
-
Jackson Laboratory
Bar Harbor, United States Active
Researchers
- Principal investigator: West, Andrew Phillip — Jackson Laboratory
- Study coordinator: West, Andrew Phillip
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
High-throughput 3D human heart tissue to screen drug safety
A Johns Hopkins team is creating a high-throughput, 3D human heart tissue model to test drug safety on human heart cells.
-
Precision imaging of heart damage from cancer treatment using metabolic MRI biomarkers
Researchers will use advanced MRI to find early metabolic signs of heart injury in cancer patients treated with common drugs, so doctors can protect the heart earlier.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.